<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940352</url>
  </required_header>
  <id_info>
    <org_study_id>CHDM201H12101C</org_study_id>
    <secondary_id>2018-004001-62</secondary_id>
    <nct_id>NCT03940352</nct_id>
  </id_info>
  <brief_title>HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or&#xD;
      venetoclax in subjects with AML or high-risk MDS.&#xD;
&#xD;
      For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in&#xD;
      exons 5, 6, 7 and 8.&#xD;
&#xD;
      Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability,&#xD;
      PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and&#xD;
      HDM201+venetoclax (treatment arm 2).&#xD;
&#xD;
        -  In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.&#xD;
&#xD;
        -  In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax.&#xD;
           Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to&#xD;
           achieve the daily target dose tested that will be subsequently continued.&#xD;
&#xD;
      Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with&#xD;
      MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment&#xD;
      arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">December 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) of treatment</measure>
    <time_frame>at day 28</time_frame>
    <description>end of first cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interuptions</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>at month 24</time_frame>
    <description>measured in mg/ day Month 24 is assumed to be study end</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453)</measure>
    <time_frame>at Day 1, Day 29 and at month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1, Day 2, Day 5, Day 6 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1 and Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>High-risk Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib (escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib (escalation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <description>Capsule</description>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>LIVI (Liquid in vial) Concentrate for Solution for infusion</description>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet</description>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥ 18 years of age at the date of ICF signature who present&#xD;
             with one of the following:&#xD;
&#xD;
               1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who&#xD;
                  have relapsed or exhibited refractory disease (primary failure) and are deemed by&#xD;
                  the Investigator not to be candidates for standard therapy, including&#xD;
                  re-induction with cytarabine or other established chemotherapy regimens for&#xD;
                  patients with AML (patients who are suitable for standard re-induction&#xD;
                  chemotherapy or hematopoietic stem cell transplantation and willing to receive it&#xD;
                  are excluded)&#xD;
&#xD;
               2. First line AML patient unfit for standard induction chemotherapy (includes both&#xD;
                  de novo and secondary AML), except in countries where approved therapies are&#xD;
                  available. Patients who are suitable for hematopoietic stem cell transplantation&#xD;
                  and willing to receive it are excluded.&#xD;
&#xD;
               3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who&#xD;
                  have failed hypomethylating agent therapy.&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and&#xD;
             determined to contain no mutations. The TP53 status must be obtained from a&#xD;
             bone-marrow sample, collected no longer than 3 months before signing the main ICF.&#xD;
&#xD;
          -  Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to&#xD;
             the institutional guidelines and be willing to undergo a bone marrow aspirate and/or&#xD;
             biopsy at screening, during and at the end of therapy on this study. Exceptions may be&#xD;
             considered after documented discussion with Novartis.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
        Patients eligible for this study must not meet any of the following criteria:&#xD;
&#xD;
          -  Prior combination treatment with compounds having the same mode of action:&#xD;
&#xD;
               -  mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in&#xD;
                  treatment arm1)&#xD;
&#xD;
               -  mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in&#xD;
                  treatment arm2)&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to any ingredient of study drug(s) and&#xD;
             other monoclonal antibodies (mAbs) and/or their excipients.&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia with PML-RARA.&#xD;
&#xD;
          -  Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD&#xD;
             requiring systemic immunosuppressive therapy.&#xD;
&#xD;
          -  GI disorders impacting absorption of oral HDM201 or venetoclax.&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis or major coagulopathy (including&#xD;
             familial).&#xD;
&#xD;
          -  Patients with active, known or suspected autoimmune disease (treatment arm 1 only).&#xD;
&#xD;
        Other eligibility criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Jones</last_name>
      <email>sfigueroa@ocli.net</email>
    </contact>
    <investigator>
      <last_name>Harry Erba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN 00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib</keyword>
  <keyword>BHLRM</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>HDM201</keyword>
  <keyword>TP53</keyword>
  <keyword>MBG453</keyword>
  <keyword>TIM-3</keyword>
  <keyword>venetoclax</keyword>
  <keyword>Bcl-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

